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Abstract: (1) Background: The atopic march is defined by the increased prevalence of allergic diseases
after atopic dermatitis onset. In fact, atopic dermatitis is believed to play an important role in
allergen sensitization via the damaged skin barrier, leading to allergic diseases such as allergic
asthma and allergic rhinitis. The eosinophil, a pro-inflammatory cell that contributes to epithelial
damage, is one of the various cells recruited in the inflammatory reactions characterizing these
diseases. Few studies were conducted on the transcriptome of this cell type and even less on their
specific microRNA (miRNA) profile, which could modulate pathogenesis of allergic diseases and
clinical manifestations post-transcriptionally. Actually, their implication in allergic diseases is not
fully understood, but they are believed to play a role in inflammation-related patterns and epithelial
cell proliferation. (2) Methods: Next-generation sequencing was performed on RNA samples from
eosinophils of individuals with atopic dermatitis, atopy, allergic rhinitis and asthma to obtain
differential counts of primary miRNA (pri-miRNA); these were also analyzed for asthma-related
phenotypes such as forced expiratory volume in one second (FEV1), immunoglobulin E (IgE) and
provocative concentration of methacholine inducing a 20% fall in forced expiratory volume in 1 s (PC20)
levels, as well as FEV1 to forced vital capacity (FEV1/FVC) ratio. (3) Results: Eighteen miRNAs from
eosinophils were identified to be significantly different between affected individuals and unaffected
ones. Based on counts from these miRNAs, individuals were then clustered into groups using Ward’s
method on Euclidian distances. Groups were found to be explained by asthma diagnosis, familial
history of respiratory diseases and allergic rhinitis as well as neutrophil counts. (4) Conclusions:
The 18 differential miRNA counts for the studying phenotypes allow a better understanding of
the epigenetic mechanisms underlying the development of the allergic diseases included in the
atopic march.
Keywords: microRNAs; miRNAs; eosinophils; atopic march; asthma; allergy; gene expression;
sequencing
1. Introduction
Allergic diseases (which include atopic dermatitis, food allergy, allergic asthma, and allergic
rhinitis) are noncommunicable diseases that have seen the greatest increase in prevalence in
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the last decades, a phenomenon described as the “allergy epidemic” [1]. In the past ten years,
allergy prevalence and hospitalization rates for severe allergic reactions has tripled [2] and our
understanding of the root causes of allergic diseases has seen a complete paradigm shift [3].
In fact, the atopic march is defined by an increased prevalence of allergic diseases in individuals
with atopic dermatitis. The latter, long considered only an epiphenomenon of allergies, has now
clearly been shown to play a central role in their development. The inflamed and disrupted skin
barrier of infants with atopic dermatitis allows the penetration of food and environmental allergenic
proteins, leading to sensitization, the first step in becoming allergic. This explains why children with
atopic dermatitis are at a high risk of developing food allergy (35% prevalence), allergic asthma (50%),
and allergic rhinitis (75%) later in life [4]. Not only is the incidence of these diseases increased with
atopic dermatitis, but they are also much more severe when compared to children without a history of
atopic dermatitis [4].
Allergic asthma, which can happen at the final stages of the atopic march, is a chronic inflammatory
disease characterized by symptoms of wheezing, shortness of breath, chest tightness, cough and
variable expiratory airflow limitation [5]. Asthma is often associated with airway hyperresponsiveness
and chronic inflammation in reaction to various stimuli including allergens, infections and air pollutants.
Causes of asthma are multiple; they include environmental and genetic factors [6]. Indeed, familial
history of asthma was found to be an important risk factor for the development of the disease, which is
characterized by a calculated heritability of 55 to 90% [7]. However, heritability only partially explains
the disease prevalence in the atopic march process. Another part of this prevalence could also be
explained by epigenetic mechanisms such as DNA methylation, histone modification and non-coding
RNAs. [8] More studies need to be conducted to better understand the influence of these mechanisms
on diseases of the atopic march, especially concerning miRNA profiles.
miRNAs are small non-coding RNAs with 19–25 nucleotides that regulate gene expression
post-transcriptionally. They silence complementary genes by targeting the 3′ untranslated region
of mRNA, repressing their expression [9]. Their maturation includes primary (pri-miRNA, up to
1000 nucleotides long) and precursor (pre-miRNA, 60–120 nucleotides long) steps [10]. miRNAs act on
various pro-inflammatory mechanisms in asthma and on smooth muscle cell proliferation, promoting
airway hyperresponsiveness and playing an essential role in its pathogenesis [11]. Some miRNAs were
also found to influence both the differentiation of T helper cells [12] and the innate immune response
in keratinocytes of atopic dermatitis patients, [13] and to be differentially expressed in subjects with
rhinitis and other allergic diseases [14,15].
Difference in miRNA profiles was also associated with other asthma-related phenotypes.
Methacholine challenge (PC20), forced expiratory volume in one second (FEV1) and FEV1 to forced
vital capacity (FEV1/FVC) ratio are all measures used as diagnostic tools or indicators of asthma
severity [16,17]. Few studies have focused on miRNA expression predicting these phenotypes,
but all three were previously associated with differential counts for certain miRNAs [18–20].
Finally, the differences in miRNA patterns that were observed for various diseases could lead to
the identification of potential biomarkers for atopic dermatitis, asthma or other allergic diseases and
even of potential therapeutic targets [8,11,21–27].
Moreover, few studies have demonstrated differential miRNA patterns in eosinophils, a type of
pro-inflammatory cells whose proliferation in airways is characteristic of certain asthma phenotypes [28].
A study by Rodrigo-Muñoz et al. found that miRNAs in these cells that are peripheral can serve as
potential diagnostic tools [29]. Another study by Allantaz et al. has shown a down-regulation of
miR-155 in eosinophils that could be implicated in inflammatory processes [30]. Studying miRNA
profiles from cell types well-known for their implication in allergic asthma is important considering
the cell-type-specific characteristics of the transcriptome.
In this study, we sought to determine if some miRNAs were differentially expressed between
individuals with allergic diseases included in the atopic march process and unaffected ones. We also
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wanted to see if they could be grouped based on their miRNA expression counts associated with
diseases of the atopic march and phenotypes.
2. Results
This study used pri-miRNA expression counts from 145 individuals of the Saguenay-Lac-Saint-Jean
(SLSJ) asthma familial cohort sampled for eosinophils in order to better understand underlying
epigenetic mechanisms of diseases included in the atopic march process. The counts were analyzed for
atopic dermatitis, atopy, allergic rhinitis, asthma, and asthma-related phenotypes (FEV1, IgE levels,
PC20 and FEV1/FVC ratio). A clustering approach with significant miRNAs was then applied to
identify potential explanations regarding the phenotypes for the differential counts of pri-miRNA
between individuals. The phenotypic characteristics of the 145 individuals are accessible in Table 1
and number of individuals presenting overlapping conditions are represented in Figure 1.







M:F ratio 1:1.04 1:1.09 1:0.67
Age, mean (range) 46 (18–81) 45 (18–81) 55 (22–72)
Age, median 47 60 44
Smoking status d
Non-smokers, n (%) 93 (64) 88 (68) 5 (33)
Ex-smokers, n (%) 29 (20) 22 (17) 7 (47)
Smokers, n (%) 22 (15) 19 (15) 3 (20)
PC20, mean mg/mL (SD) e 1.76 (1.67) 1.5 (1.57) 3.75 (0.76)
IgE, mean µg/L (SD) f 4.93 (1.67) 5.09 (1.67) 3.61 (0.97)
FEV1, mean% pred. (range) g 94.72 (31–146) 94.25 (31–46) 98.6 (65–119)
FEV1/FVC ratio, mean (range) h 79.09 (38–97) 94.25 (38–97) 82.43 (68–96)
White blood cell count i
Eosinophil, mean × 109/L (%) 0.25 (3.76) 0.26 (3.96) 0.15 (2.18)
Lymphocyte, mean × 109/L (%) 2.15 (32.12) 2.15 (32.05) 2.03 (31.43)
Monocyte, mean × 109/L (%) 0.52 (7.89) 0.53 (7.88) 0.50 (8.01)
Neutrophil, mean × 109/L (%) 3.80 (55.60) 3.82 (55.45) 3.72 (57.89)
Basophil, mean × 109/L (%) 0.04 (0.78) 0.05 (0.77) 0.04 (0.89)
Asthma, n (%) j 89 (61.81)
Allergic rhinitis, n (%) k 54 (37.50)
Atopic dermatitis, n (%) l 75 (52.08)
a Number of eosinophil samples for which the sequencing of whole transcriptome data as well as covariates for
analyses was available. b Number of affected individuals. Total affected individuals are individuals with either
atopic dermatitis, atopy, asthma or allergic rhinitis, or a combination of these diseases. In this sense, depending on
the studied phenotype, the number of affected individuals will be lesser while the number of unaffected individuals
will be higher. c Number of unaffected individuals. Unaffected individuals were individuals with no disease of the
atopic march. d Ex-smokers are defined as individuals who stopped smoking for at least one year. Smoking status
was not available for one individual. e The geometric mean provocative concentration of methacholine inducing
a 20% fall in forced expiratory volume in 1 s (PC20), calculated from 130 individuals. f The geometric mean of
immunoglobulin E (IgE) levels measured from 142 individuals. g The mean forced expiratory volume in 1 s (FEV1)
as % of predicted value calculated from 138 individuals. h The mean FEV1 (L)/FVC (forced vital capacity; L) ratio
calculated as % for 128 individuals. i Whole blood eosinophil, lymphocyte, monocyte, neutrophil and basophil
cell counts obtained using a Coulter LH 780 hematology analyzer. j Present or past documented clinical history of
asthma. Status is available for 145 individuals. k Personal history of allergic rhinitis symptoms available for the
145 individuals. l Personal history of atopic dermatitis available for the 145 individuals.
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Figure 1. Number of individuals presenting overlapping conditions of the atopic march. Overall, 75 
individuals presented atopic dermatitis, 89 had allergic asthma and 54 had allergic rhinitis. Several of 
these individuals had overlapping conditions, highlighting the increased risk of presenting an allergic 
disease as allergic asthma or allergic rhinitis if an individual has atopic dermatitis. 
2.1. Differential Counts of Pri-miRNA Associated with Allergic Diseases Included in the Atopic March 
The negative binomial regression model performed for each trait (atopic dermatitis, atopy, 
asthma, allergic rhinitis, FEV1, IgE levels, PC20 and FEV1/FVC ratio) allowed us to find 18 miRNAs 
with significant differences in expression counts for the eosinophil cell type (Table 2). One miRNA 
was found to be up-regulated in atopic dermatitis (fold change (FC) = 1.85), ten miRNAs were down-
regulated in asthma (FC from −2.57 to −1.10), three miRNAs were positively correlated with IgE level 
(rho from 0.02 to 0.19) as well as four miRNAs with PC20 level (rho from 0.11 to 0.18). The distribution 
of counts for each significant miRNA in accordance with the testing phenotypes is represented in 
Figure 2. 
Table 2. Significant associations (FDR < 0.05) between pri-miRNAs expression counts and diseases 
included in the atopic march process or related phenotypes. 
miRNA Phenotype Observed p-Value FDR a FC or rho b 
miR-1276 Asthma 4.511 × 10−4 0.032 −2.136 
miR-29B2 Asthma 7.260 × 10−4 0.040 −1.334 
miR-3175 Asthma 5.920 × 10−5 0.013 −1.118 
miR-33B Asthma 4.971 × 10−4 0.032 −1.235 
miR-4308 Asthma 5.039 × 10−4 0.032 −1.856 
miR-4523 Asthma 1.195 × 10−4 0.018 −1.182 
miR-4673 Asthma 2.164 × 10−4 0.024 −2.020 
miR-4785 Asthma 0.001 0.047 −1.328 
miR-590 Asthma 8.479 × 10−4 0.041 −1.100 
miR-638 Asthma 1.010 × 10−5 0.004 −2.570 
miR-614 Atopic dermatitis 1.190 × 10−6 5.239 × 10−4 1.847 
miR-142 IgE 3.940 × 10−8 1.730 × 10−5 0.112 
miR-3064 IgE 4.880 × 10−5 0.007 0.185 
miR-4434 IgE 4.060 × 10−5 0.007 0.134 
miR-1304 PC20 1.920 × 10−6 8.428 × 10−4 0.105 
miR-2355 PC20 7.120 × 10−5 0.013 0.128 
miR-26A2 PC20 2.054 × 10−5 0.023 0.192 
miR-645 PC20 8.540 × 10−5 0.013 0.024 
a Significance level for the difference of pri-miRNA expression counts according to phenotypic traits 
corrected using a false discovery rate (FDR) method. b Fold change (FC) or Spearman’s rho calculated 
depending on the phenotypic data type. Fold change was calculated for asthma and atopic dermatitis 
phenotypes. miRNAs with a positive fold change were considered up-regulated in affected 
individuals while miRNAs with a negative fold change were down-regulated. Spearman’s rho was 
calculated for IgE and PC20 levels. Positive rho values indicate positive correlations between the pri-
miRNA counts and the phenotype. 
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2.1. Differential Counts of Pri-miRNA Associated with Allergic Diseases Included in the Atopic March
The negative binomial regression model performed for each trait (atopic dermatitis, atopy, asthma,
allergic rhinitis, FEV1, IgE levels, PC20 and FEV1/FVC ratio) allowed us to find 18 miRNAs with
significant differences in expression counts for the eosinophil cell type (Table 2). One miRNA was found
to be up-regulated in atopic dermatitis (fold change (FC) = 1.85), ten miRNAs were down-regulated in
asthma (FC from −2.57 to −1.10), three miRNAs were positively correlated with IgE level (rho from
0.02 to 0.19) as well as four miRNAs with PC20 level (rho from 0.11 to 0.18). The distribution of counts
for each significant miRNA in accordance with the testing phenotypes is represented in Figure 2.
Table 2. Significant associations (FDR < 0.05) between pri-miRNAs expression counts and diseases
included in the atopic march process or related phenotypes.
miRNA Phenotype Observed p-Value FDR a FC or rho b
miR-1276 Asthma 4.511 × 10−4 0.032 −2.136
miR-29B2 Asthma 7.260 × 10−4 0.040 −1.334
miR-3175 Asthma 5.920 × 10−5 0.013 −1.118
miR-33B Asthma 4.971 × 10−4 0.032 −1.235
miR-4308 Asthma 5.039 × 10−4 0.032 −1.856
miR-4523 Asthma 1.195 × 10−4 0.018 −1.182
miR-4673 Asthma 2.164 × 10−4 0.024 −2.020
miR-4785 Asthma 0.001 0.047 −1.328
miR-590 Asthma 8.479 × 10−4 0.041 −1.100
miR-638 Asthma 1.010 × 10−5 0.004 −2.570
miR-614 Atopic dermatitis 1.190 × 10−6 5.239 × 10−4 1.847
miR-142 IgE 3.940 × 10−8 1.730 × 10−5 0.112
miR-3064 IgE .880 × 10−5 0.007 0.185
miR-4434 IgE .060 × 10−5 0.007 0.134
miR-1304 PC20 .920 × 10−6 8.428 × 1 −4 0.105
miR-2355 PC20 .120 × 10−5 0.013 0.128
miR-26A2 PC20 2.054 × 10−5 0.023 0.192
miR-645 PC20 8.540 × 10−5 0.013 0.024
a Significance level for the difference of pri-miRNA expression counts according to phenotypic traits corrected
using a false discovery rate (FDR) method. b Fold change ( C) or Spearman’s rho calculated depending on the
phenotypic data type. Fold change was calculated for asthma and atopic dermatitis phenotypes. miRNAs with
a positive fold change were considered up-regulated in affected individuals while miRNAs with a negative fold
change were down-regulated. Spearman’s rho was calculated for IgE and PC20 levels. Positive rho values indicate
positive correlations between the pri-miRNA counts and the phenotype.
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Figure 2. Significant pri-miRNA expression counts by phenotypes. Plots (A–J) show down-regulation of ten pri-miRNAs in asthmatic patients compared to non-
asthmatics, while plot (K) shows up-regulation of miR-614 for individuals with atopic dermatitis in comparison with unaffected ones. As for plots (L–O), they 
display positive correlations between miRNAs and PC20 levels. Lastly, plots (P–R) show positive correlation between miRNAs and IgE levels. Overall p-value of the 
analysis is in lower-left corner of each graph with corresponding fold change or Spearman’s rho value. 
 
Figure 2. Significant pri-miRNA expression counts by phenotypes. Plots (A–J) show down-regulation of ten pri-miRNAs in asthmatic patients compared to
non-asthmatics, while plot (K) shows up-regulation of miR-614 for individuals with atopic dermatitis in comparison with unaffected ones. As for plots (L–O),
they display positive correlations between miRNAs and PC20 levels. Lastly, plots (P–R) show positive correlation between miRNAs and IgE levels. Overall p-value of
the analysis is in lower-left corner of each graph with corresponding fold change or Spearman’s rho value.
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2.2. Clustering of Significant miRNAs
Using Ward’s method on Euclidian distances for the significant miRNAs, six clusters were obtained
(Figure 3). Analyses were then performed to define which phenotypic elements characterize them.
Clusters 1, 4 and 5 were ignored in analyses because they contained three individuals or less. As for
clusters 2, 3 and 6, they included, respectively, 52, 69 and 19 individuals and were kept for subsequent
steps. See Table S1 for a detailed view of all the phenotypes for comparing clusters. These were found
to be explained by asthma phenotype, familial history of respiratory diseases and allergic rhinitis as
well as neutrophil counts (Figure 4).
Moreover, looking at Figure 4 and according to post-hoc analyses, cluster 2 was associated with
higher rates of diagnosis of asthma as compared with cluster 6 (p-value = 0.027). Cluster 3 was less
related to familial history of respiratory diseases as clusters 2 (p-value = 0.033) and 6 (p-value = 0.034).
Cluster 6 also had a stronger association with familial history of allergic rhinitis when compared with
clusters 2 (p-value = 0.009) and 3 (p-value = 0.003). Finally, cluster 2 had a higher neutrophil count in
comparison with clusters 3 (p-value = 0.035) and 6 (p-value = 0.005).
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Figure 3. Clustering of individuals according to significant pri-miRNAs counts. Individuals were 
clustered according to expression counts from the 18 associated miRNAs using Ward’s method on 
Euclidian distances. Six clusters were then obtained by visual inspection of the dendrogram and 
confirmed with the NbClust package in R. 
Figure 3. Clustering of individuals according to significant pri- iRNAs counts. Individuals were
clustered according to expression counts from the 18 associated miRNAs using Ward’s method on
Euclidian distances. Six clusters were then obtained by visual inspection of the dendrogram and
confirmed with the NbClust package in R.
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Figure 4. Phenotypic differences underlying clustering of individuals. Significant differences between 
individuals of the three main clusters (including more than three people) were found for: (A) asthma; 
(B) familial history of respiratory diseases; (C) familial history of allergic rhinitis; and (D) neutrophil 
cell count. Overall p-value of the analysis is in the upper-right corner of each graph and the number 
above each cluster indicates the other clusters that are significantly different in post-hoc analyses. An 
asterisk indicates significant difference after Bonferroni correction. 
2.3. Identifiaction of Possible Gene Targets 
In order to better understand underlying mechanisms explaining associations observed between 
pri-miRNA expression and diseases of the atopic march or clinical measures, correlations were 
performed to identify possible gene targets. miRNA–gene target pairs with false discovery rate 
(FDR)-values inferior to 0.05 and absolute correlation coefficients >0.2 were deemed significant and 
further validated using miRTArBase v8.0 [31]. A total of 540 validated miRNA–gene target pairs were 
found using negative correlations and 663 using positive correlations. According to the inhibition 
function of miRNAs, results of negative correlations are usually prioritized. However, a recent study 
highlighted the mechanisms underlying positive correlations with gene targets, such as in feedback 
loops and co-transcription of intronic miRNAs and their host genes [32], motivating the presentation 
of positive correlations in this study. The top 25 best negative and positive correlations are displayed 
in Table S2. They were then classified into PANTHER biological pathways [33]. Among the gene 
targets identified, 215 from the negative correlations and 353 from the positive ones have been 
successfully classified by PANTHER. Biological pathways identified were grouped into more general 
Figure 4. Phenotypic differences underlying clustering of individuals. Significant differences between
individuals of the three main clusters (including more than three people) were found for: (A) asthma;
(B) familial history of respiratory diseases; (C) familial history of allergic rhinitis; and (D) neutrophil
cell count. Overall p-value of the analysis is in the upper-right corner of each graph and the number
above each cluster indicates the other clusters that are significantly different in post-hoc analyses.
An asterisk indicates significant difference after Bonferroni correction.
2.3. Identifiaction of Possible Gene Targets
In order to better understand underlying mechanisms explaining associations observed between
pri-miRNA expression and diseases of the atopic march or clinical measures, correlations were
performed to identify possible gene targets. miRNA–gene target pairs with false discovery rate
(FDR)-values inferior to 0.05 and absolute correlation coefficients >0.2 were deemed significant and
further validated using miRTArBase v8.0 [31]. A total of 540 validated miRNA–gene target pairs were
found using negative correlations and 663 using positive correlations. According to the inhibition
function of miRNAs, results of negative correlations are usually prioritized. However, a recent study
highlighted the mechanisms underlying positive correlations with gene targets, such as in feedback
loops and co-transcription of intronic miRNAs and their host genes [32], motivating the presentation of
positive correlations in this study. The top 25 best negative and positive correlations are displayed in
Table S2. They were then classified into PANTHER biological pathways [33]. Among the gene targets
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identified, 215 from the negative correlations and 353 from the positive ones have been successfully
classified by PANTHER. Biological pathways identified were grouped into more general categories
shown in Figure 5 (see Table S3 for the list of PANTHER pathways in each general category).
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correlations with associated miRNAs. The number of genes is indicated for each category. (A) Pathways
for negatively correlated miRNA–gene target pairs. (B) Pathways for positively correlated miRNA–gene
target pairs.
Finally, gene targets found were compared to the genes already associated with diseases of the
atopic march in the GWAS Catalogue (42 for negative correlations and 53 for positives ones) and the
SLSJ asthma familial cohort (13 for the negative correlations and 22 for the positive ones; Table S4).
Table 3 represents those gene targets that are included in PANTHER biological pathways. Negative
correlations included eight gene targets associated in GWAS analyses and four were associated in
the SLSJ cohort. Positive correlations included 19 gene targets associated in GWAS and nine were
associated in the SLSJ cohort. Total resulting number of targets for positive and negative correlations
before and after validation, as well as number of genes found in GWAS Catalogue and literature about
the SLSJ asthma familial cohort are detailed in Table S4.
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Table 3. miRNAs’ gene targets previously associated in GWAS as listed by the GWAS Catalogue or in the Saguenay-Lac-Saint-Jean (SLSJ) cohort and classified by
PANTHER pathways.
Pathway Nb of Gene Targets GWAS Associated Genes a SLSJ Associated Genes a
Negative correlation
Cell growth, division, differentiation
and apoptosis 64 COL15A1, SOCS1, BCL2L1, DUSP2, SSR3 COL15A1, SOCS1
Immune response 33 FER, IL6
Protein cleavage, biosynthesis
and modification 21 BACE2
DNA and RNA synthesis and replication 19 MAT2A
Aldehyde transport and reactions 2 DCAKD
Positive correlation
Cell growth, division, differentiation
and apoptosis 158
APC, CASP8, CRK, DUSP2, FOS, FRS2,
HSPA1B, PRKCD, RTF1, SKI, TGFBR1 HSPA1B, HSPA6, YWHAZ
Brain, neurotransmission and
nervous system 44 ALDH1A2, CDC42 ARHGEF1
Immune response 38 REL, TNFA1P3 CDNK1B, STAT3
Protein cleavage, biosynthesis
and modification 35 INO80, LRP3 MMP9
Hormonal regulation 29 NAB2, POU2F1 LDB1, SP1
a Genes in blue are those that are associated with allergic diseases included in the atopic march according to the GWAS Catalogue and as well as in studies performed in the
Saguenay-Lac-Saint-Jean (SLSJ) asthma familial cohort.
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3. Discussion
This research used pri-miRNA counts obtained by next-generation sequencing of the whole
eosinophil transcriptome, a cell known to play an inflammatory role in asthma [28], for finding
differential expression of certain miRNAs between patients having allergic diseases often associated
with the atopic march and controls in order to better understand epigenetic mechanisms underlying
these phenomena. Specifically, it was previously noted that eosinophils can carry miRNAs via exosomes
to other cells; they are becoming not only a pro-inflammatory cell type, but also a vector for miRNAs
and a potential regulator of gene expression [34]. In this sense, extracting miRNAs from eosinophils
allows a better understanding of their effect on diseases in the atopic march process as compared to
those from whole blood. Overall, miRNAs extracted from eosinophils improve the knowledge of their
possible roles in proliferation of the inflammatory cells and immune functions in these diseases [35,36].
The miRNA levels measured from eosinophil cells extracted as part of this study allowed us to
identify 18 that were differentially expressed between individuals with allergic diseases and unaffected
ones, as well as for IgE levels and PC20. Five of them were associated in the past with asthma and allergic
diseases (miR-142 [37,38], -26a [39,40], -29b [41,42], -590 [29,43] and -638 [44]). In fact, the miRNA
expression counts of these five miRNAs were all differentially regulated in the same direction as that is
found in literature. Three were previously associated with other respiratory conditions including lung
cancer (miR-1276 [45], -1304 [46] and -33b [47]), hypopharyngeal cancer (miR-1304 [48]) and cystic
fibrosis (miR-1276 [49]). Finally, three were previously associated with diseases involving inflammatory
components (miR-2355 [50], -3175 [51], -33b [52]). This study led to the identification of 13 miRNAs
not previously associated with allergic diseases or asthma. The remaining five miRNAs were already
found to have a differential expression in diseases of the atopic march, but this study allowed the
confirmation that these were also differentially expressed in eosinophils. There are very few studies
on miRNA expression in eosinophil samples for allergic diseases. A study by Rodrigo-Muñoz et al.
found 21 miRNAs differentially expressed in eosinophils in asthma, from which miR-590 was also
down-regulated [29]. No significant differences were observed for the 20 other miRNAs in our study.
This could be explained by their smaller sample size (29 asthmatic and 10 healthy individuals), the fact
that they did not study an allergic endotype of asthma as done in this project, and also because we
measured differential pri-miRNA counts as compared to mature miRNAs in their study. However,
measuring pri-miRNA counts allow a more direct understanding of miRNA transcription. Finally,
even though no mature miRNA data were available, several pri-miRNAs were previously associated
with mature miRNAs in allergic diseases included in the atopic march process. Moreover, the target
analysis of the significant miRNAs associated in this study found CITED2 as a target of miR-590, a gene
regulating TGF-beta pathways acting on airway smooth muscle cell proliferation. In fact, eosinophils
have previously been shown to enhance gene expression of TGF-beta1 and to increase airway smooth
muscle cell proliferation [53]. In this sense, it is expected that this miRNA can be differentially regulated
in both allergic and non-allergic endotypes of asthma. These findings point toward a regulatory role
in these diseases. Finally, considering modest coefficients of correlations found between pri-miRNA
counts and PC20 and IgE levels, we hypothesize that such correlations are more complex than mere
direct interaction. In fact, Davis et al. have found that certain miRNAs could modulate PC20 by
increasing airway smooth muscle cell diameter [18]. Therefore, more studies need to be done in order
to better define links between these miRNAs and biological measures.
Actually, some well-known miRNAs in asthma and allergic diseases such as miR-221, -485-3p,
-1248, -126, -146a/b, -28-5p, -181a, -133a or -10a [23] were not replicated in this study. Among these,
four miRNAs were expressed in eosinophil samples, but their corresponding pri-miRNAs did not
show significant differences according to the phenotype status. However, based on the cell-type
specificity of transcriptome measurements, it was expected that eosinophils will have a distinct profile
in comparison to whole blood. It was demonstrated in the past that whole blood miRNAs are derived
from various exosomes specific to cell types; this means previously found differential miRNA counts
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associated with diseases in the atopic march process could be derived from other ones like lymphocytes,
dendritic cells, platelets, mastocytes, epithelial cells, endothelial cells or neurons [54].
To further understand the links between pri-miRNA expression counts and phenotypic differences
in asthma and allergic diseases, individuals were clustered into three distinct groups based on the
pri-miRNA counts for each of the 18 previously associated miRNAs. These clusters featured significant
differences, which is consistent with the proportion of subjects having asthma phenotype as well as
familial history of respiratory diseases and allergic rhinitis, further confirming the family component
in them [6]. Moreover, earlier studies have associated asthma prevalence with allergic rhinitis [55–57];
these findings tend to demonstrate a link between the two. However, more studies need to be done in
regard to the similarities between the eosinophil miRNA patterns between asthma and allergic rhinitis
to reach such a conclusion. A difference in counts of circulating neutrophils, a cell type characterizing an
asthma endotype not typically linked with allergies [58], was also observed. With a higher proportion
of individuals with familial history of allergic rhinitis and a smaller neutrophil count, cluster 6 shows a
higher number of allergic individuals, even though its proportion of asthmatics is lower. However, it is
important to note the smaller number of individuals included in this cluster (19 compared to 52 and
69). Interestingly, many miRNAs turned out to be differentially regulated in cluster 6, as compared to
clusters 2 and 3. These miRNAs were previously found to play a role in diseases of the atopic march.
It is the case for miR-142 [37,38], -26a [39,40], -29b [41,42], -590 [29,43] and -638 [44] which all had
higher counts in cluster 6, in comparison with clusters 2 and 3. Similarly, both clusters 2 and 3 showed
higher values for miR-1276 and -1304 whereas cluster 3 showed higher values for miR-33b and -2355,
four miRNAs known for their implication in non-allergic respiratory diseases [45–50]. Furthermore,
no association was made with eosinophil counts in the clustering approach. This could be explained
by the fact that the eosinophil cell counts were similar between affected (by one or more allergic
disease) and non-affected (by none of the allergic diseases tested) individuals. However, there is
indeed a difference in eosinophil cell counts when we compare for a single disease such as asthma,
with a mean of 0.29 × 109/L eosinophils in individuals with asthma and 0.18 × 109/L in unaffected
ones. However, miRNAs associated in eosinophil samples were not necessarily linked with biological
pathways involved in eosinophil recruitment or proliferation.
To further understand the implication of these miRNAs on diseases of the atopic march, an analysis
to identify possible gene targets was performed. The 18 associated pri-miRNA expression counts
were significantly correlated with several targets previously identified in diseases of the atopic march.
Overall, 95 gene targets were already associated with diseases of the atopic march in the GWAS
Catalogue and 35 with the SLSJ asthmatic cohort. Among gene targets that were linked with biological
pathways, 42 were also associated with diseases of the atopic march, either in the GWAS Catalogue
or in the SLSJ cohort. Those genes were classified into pathways including cell regulation, immune
response, smooth muscle cell proliferation and angiogenesis, further confirming the importance of
miRNAs in these diseases. However, further studies are needed to better understand the specific link
between these 18 miRNAs and the different diseases of the atopic march.
This study sought to find a differential miRNA pattern in eosinophils from patients presenting
with diseases in the atopic march process and unaffected individuals. Eighteen miRNAs turned out to
be differentially expressed in eosinophil samples in case of either atopic dermatitis or asthmatic statuses
than in unaffected individuals, or according to the PC20 or IgE levels. Moreover, the clustering approach
used with the associated miRNAs revealed a link between these and fine phenotypic information
defining the individuals included in this study and allowed identifying the miRNAs that are more likely
to be involved specifically in the atopic component of the studied diseases among the 18 in association.
Overall, these miRNAs could help improve the knowledge of post-transcriptional regulation
leading to allergic diseases included in the atopic march process. In fact, their differential regulation
found in eosinophils help refine our understanding of miRNAs in these diseases and their important
role in gene expression regulation. Finally, the presence of multiple atopic diseases in one patient
may imply the relevance of miRNAs in the atopic march. However, birth cohorts and longitudinal
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studies will need to be performed to support this hypothesis. Despite this, it is interesting to note that
a previous study including the SLSJ cohort and a birth cohort aiming at developing a polygenic risk
score for moderate-to-severe atopic dermatitis, the sub-phenotype of atopic dermatitis associated with
the highest risk to develop the atopic march, also showed good discriminative values for allergies,
allergic asthma and allergic rhinitis in the SLSJ cohort [59].
4. Materials and Methods
4.1. SLSJ Asthma Cohort
The SLSJ asthma familial cohort comprises 1394 individuals distributed in 271 families from
which 1214 subjects have genotypic information. Pulmonary health of each individual was evaluated
according to the American Thoracic Society (ATS) Clinical Practice Guidelines using a standardized
questionnaire and pulmonary function testing [60]. The subpopulation used for this study was selected
using siblings with discordant asthma status and from trios of affected probands and discordant parents
regarding asthma status. Using these criteria, 215 subjects were obtained to isolate their eosinophils
for RNA sequencing. Asthma and atopy phenotypes were defined according to ATS standards [61].
Participants were considered as asthmatic if: (1) they had a reported history of asthma (validated
by a physician), or (2) they presented asthma-related symptoms and positive PC20 (<8 mg/mL) at
recruitment. Individuals were deemed atopic if they had at least one positive response on skin prick
tests (wheal diameter ≥ 3 mm or larger than the wheal diameter elicited by the negative control
(glycerin)) and have a physician diagnosis. Atopic dermatitis and allergic rhinitis were self-reported and
were considered as positive if past or present occurrence of these diseases was reported. For children,
cross validation was done using questionnaires filled out by their parents. Moreover, validation in
medical records of these self-reported phenotypes were done for a subset of the SLSJ Cohort (n = 217),
giving 89% concordance. Proportions of white blood cells were obtained using a Coulter LH 780
hematology analyzer (Beckman Coulter, Mississauga, ON, Canada) to estimate proportion of five
different types of white blood cells: eosinophils, lymphocytes, neutrophils, monocytes and basophils.
Respiratory measures such as PC20 and FEV1 were taken using a Morgan spirometer (Morgan Spiro
232, P.K. Morgan Ltd., Kent, UK) [62]. Complete descriptions of both recruitment and evaluation
used for the SLSJ cohort can be found in Laprise et al. [62] All participants gave informed consent
and the study was approved by the Centre intégré universitaire de santé et de services sociaux du
Saguenay–Lac-Saint-Jean ethics committee (project #0002-001, 08-11-2005).
4.2. Isolation of RNA from Eosinophils and Sequencing
Complete description of the procedure for eosinophil isolation can be found in Madore et al. [63]
Briefly, eosinophils were isolated by negative selection from 200 mL blood samples with anti-CD16,
anti-CD3 and anti-CD19 MicroBeads (Miltenyi Biotec, Auburn, CA, USA) and a proportion of cells
(2 × 106) was used for total RNA extraction (molecules ≥ 200 nucleotides). This step was performed
with the RNeasy Mini Kit following manufacturer’s instructions (Qiagen, Toronto, ON, Canada).
RNA sequencing was carried out at the McGill University and Genome Québec Innovation Center
using TruSeq Stranded Total RNA Sample Prep kit (Illumina, Vancouver, BC, Canada). Final libraries
were quality controlled on a Bioanalyzer (Agilent Technologies, Mississauga, ON, Canada) and
underwent 100 bp paired-end sequencing on the Illumina HiSeq2000 System (Illumina, Vancouver, BC,
Canada). Generated raw reads were filtered for quality (phred33 ≥ 30) and length (n ≥ 32) as well as
adapter sequences were removed using Trimmomatic v.0.32 as previously described [63]. Considering
the length of the extracted RNAs (≥200 nucleotides), expression counts were available for pri-miRNAs.
After quality control filtering, 441 pri-miRNA were available for analyses. From the 215 initial
individuals, considering the large amount of blood necessary for RNA sequencing, quality filtering
applied and the covariates availability for statistical analysis, pri-miRNA counts were accessible for 145
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of them. These results reflect the transcription of miRNA sequences without necessarily quantifying
the abundance of the mature miRNAs [10].
4.3. Statistical Methods
4.3.1. Analyses of Pri-miRNA Expression Counts between Individuals
Pri-miRNA expression counts were compared with a negative binomial regression model built
with pri-miRNA normalized expression counts and phenotypes using the MASS package in R. Studied
phenotypes were atopic dermatitis (75 affected, 70 healthy), atopy (94 affected, 51 healthy), allergic
rhinitis (54 affected, 91 healthy), asthma (89 affected, 56 healthy), FEV1, IgE levels, PC20 and FEV1/FVC
ratio. Age, sex, smoking history, eosinophil proportion and surrogate variables were used as covariates.
Proportions of eosinophils were calculated working with methylome data from the same eosinophil
samples as well as the method by Houseman implemented in the R package RnBeads as described
above (Table S5) [64,65]. Surrogate variables were evaluated using the R package sva in order to account
for batch effects, relatedness between samples and other hidden confounders [66]. Normalization
of miRNAs expression counts on library size was done with the DESeq2 package. Differences in
these with a FDR-value <0.05 were deemed significant. FC were calculated using the mean ratios
for affected and non-affected individuals in case of analyses taking into account the disease status
whereas Spearman’s rank correlation was performed between pri-miRNA counts and continuous
phenotypes. miRNAs with positive FC were considered up-regulated while those with negative FC
were down-regulated in the affected group of each allergic disease analyzed.
4.3.2. Clustering of miRNAs
Significant miRNAs were used to cluster individuals with Ward’s method on Euclidian distances
in R, as described by O’Sullivan et al. [67] Groups were determined by visual inspection of the
dendrogram and confirmed using the NbClust package in R. An explanation for these clusters
was then searched comparing the phenotypic measures between groups with Fisher’s exact test for
binary data, one-way ANOVA for continuous normally distributed variables and Kruskal–Wallis
test for continuous non-normally distributed ones. Post-hoc analyses were performed afterward to
find pairwise differences between clusters using Fisher’s exact test, Tukey’s test and Dunn’s test,
respectively, followed by Bonferroni corrections. Clusters with three individuals or less were ignored
from this testing (data available for 139 subjects on the 145 included in the pri-miRNA analysis).
4.3.3. Identification of Possible Gene Targets for Associated Pri-miRNAs
Negative and positive correlations were applied between the 18 associated pri-miRNA and
gene log-transformed expression count in order to find which genes are possible gene targets.
Correlations that reached an FDR-value <0.05 and an absolute correlation coefficient > 0.2 were deemed
significant. These miRNA–gene target pairs were then validated with miRTarBase v8.0 [31], a database
that list gene targets of miRNAs that were observed using technical approaches (e.g., qRT-PCR,
next-generation sequencing), in order to find which of the significant genes are more likely to be
real targets. These targets were classified according to their PANTHER pathways [33]. Gene targets
that were previously associated with diseases of the atopic march were identified using the GWAS
Catalogue (https://www.ebi.ac.uk/gwas/) and studies from the SLSJ asthma familial cohort. The GWAS
Catalogue list all human genome-wide associations for studies targeting 100,000 single nucleotide
polymorphisms (SNPs) or more and with p-values <10 × 10−5.
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